Trial Profile
Factors associated with dose escalation or cessation of vedolizumab in patients with inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2018
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- 18 Jan 2018 New trial record